Trial Profile
Usefulness of FAMT-PET to predict the response after nivolumab in patients with previously treated advanced non-small cell lung cancer
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Diagnostic use
- 29 Dec 2018 Status changed from recruiting to suspended.
- 13 Dec 2016 New trial record